{"comparisonGroups":["Normal_control_no_tumor","FH_deficient_RCC"],"dateCreated":"2025-09-26 00:00:00","display_title":"Healthy controls vs FH-deficient renal cell carcinoma","group_a_title":"Samples from healthy individuals with no tumor.. Provides a reference for identifying metabolic changes specific to RCC.","group_b_title":"Samples from patients with FH-deficient renal cell carcinoma.. Key group for identifying metabolic biomarkers associated with FH-deficient RCC.","id":"MTBLS3628_0005_00000004","pvalueThreshold":0.05,"ratioThresholdLower":"1/1.5","ratioThresholdUpper":1.5,"significantFeatures":2,"studyId":"MTBLS3628","studyUrl":"http://integmet.org/study/MTBLS3628","title":"Normal_control_no_tumor_vs_FH_deficient_RCC","topHits":[{"chebi_id":"157780","direction":"up","inn_name":"","iupac_name":"2-(2-amino-2-carboxyethyl)sulanylbutanedioic acid","metabolite_id":"XPKKFTKCRVIDAG-UHFFFAOYSA-N","pvalue":2.8174538915692017e-06,"ratio":39.146200892941934,"synonym_name":""},{"chebi_id":"71169","direction":"up","inn_name":"","iupac_name":"(2<i>S</i>)-2-({9-[(2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>R</i>)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-9<em>H</em>-purin-6-yl}amino)butanedioic acid","metabolite_id":"VKGZCEJTCKHMRL-VWJPMABRSA-N","pvalue":0.000249236329671,"ratio":17.738188072825867,"synonym_name":"<em>N</em>-(9-\u03b2-<small>D</small>-ribofuranosyl-9<em>H</em>-purin-6-yl)-<small>L</small>-aspartic acid"}],"totalFeatures":2}